Exendin-4 regulates redox homeostasis in rats fed with high-fat diet.
Acta Biochim Biophys Sin (Shanghai) · 2015
Last updated 2026-05-28In rats fed a high-fat diet, a drug called exendin-4 (a GLP-1 receptor agonist) increased levels of an enzyme called CBS and boosted glutathione (GSH), a key antioxidant, by 50%. It also reduced malondialdehyde, a marker of liver damage, while lowering homocysteine levels linked to liver disease.
AI summary of the abstract below.
| Journal | Acta Biochim Biophys Sin (Shanghai), 2015 |
|---|---|
| Citations | 15 |
| Relative citation ratio | 0.60 |
| NIH percentile | 34 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Non-alcoholic fatty liver disease (NAFLD) is associated with increased plasma homocysteine level, which is caused by down-regulation of hepatic cystathionine beta-synthase (CBS) activity. CBS catalyzes the first step in the transsulfuration of homocysteine to cysteine, which contributes ∼50% of the cysteine required for hepatic biosynthesis of glutathione (GSH), the most abundant antioxidant in cells. As the glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. exendin-4) effectively reverse hepatic steatosis, the effect of exendin-4 on both homocysteine and redox status was investigated in the livers of rats fed with high-fat diet (HFD). It was found that HFD down-regulated CBS protein expression, which was probably due to induction of rno-miR-376c expression in the liver. The level of GSH was markedly reduced, whereas the level of malonydialdehyde, an indicator of lipid peroxidation, was significantly increased in the livers of rats fed with HFD. Exendin-4 treatment increased hepatic CBS protein and GSH levels, and reduced malonydialdehyde level in hyperlipidemic rats. Our findings suggest that GLP-1 receptor agonists have beneficial effects on redox homeostasis in NAFLD.
Verbatim abstract via PubMed 25910576 ↗